Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease

BACKGROUND: Anemia is a prevalent situation in patients with chronic kidney disease (CKD) and can be well managed with erythropoiesis-stimulating agents (ESAs). Continuous erythropoietin receptor activator (CERA) has a long half-life that allows to be administered once monthly. The lowest recommende...

詳細記述

保存先:
書誌詳細
出版年:Hippokratia
主要な著者: Vega, A, Abad, S, Verdalles, U, Aragoncillo, I, Velazquez, K, Quiroga, B, Escudero, V, López-Gómez, JM
フォーマット: Artigo
言語:Inglês
出版事項: SOCIETY OF "FRIENDS OF HIPPOKRATIA JOURNAL" 2014
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453804/
https://ncbi.nlm.nih.gov/pubmed/26052197
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料